276 related articles for article (PubMed ID: 12937076)
1. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
[TBL] [Abstract][Full Text] [Related]
2. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
3. Locomotor response to levodopa in fluctuating Parkinson's disease.
Moore ST; MacDougall HG; Gracies JM; Ondo WG
Exp Brain Res; 2008 Feb; 184(4):469-78. PubMed ID: 17828529
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.
Torstenson R; Hartvig P; Långström B; Westerberg G; Tedroff J
Ann Neurol; 1997 Mar; 41(3):334-40. PubMed ID: 9066354
[TBL] [Abstract][Full Text] [Related]
5. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
[TBL] [Abstract][Full Text] [Related]
6. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Adams JR; van Netten H; Schulzer M; Mak E; Mckenzie J; Strongosky A; Sossi V; Ruth TJ; Lee CS; Farrer M; Gasser T; Uitti RJ; Calne DB; Wszolek ZK; Stoessl AJ
Brain; 2005 Dec; 128(Pt 12):2777-85. PubMed ID: 16081470
[TBL] [Abstract][Full Text] [Related]
7. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
8. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Sossi V; de la Fuente-Fernández R; Schulzer M; Adams J; Stoessl J
Brain; 2006 Apr; 129(Pt 4):1050-8. PubMed ID: 16476675
[TBL] [Abstract][Full Text] [Related]
9. PET studies and physiopathology of motor fluctuations in Parkinson's disease.
Linazasoro G; Leenders KL
Brain; 2004 Aug; 127(Pt 8):E15; author reply E16. PubMed ID: 15277309
[No Abstract] [Full Text] [Related]
10. Visualizing vesicular dopamine dynamics in Parkinson's disease.
de la Fuente-Fernández R; Sossi V; McCormick S; Schulzer M; Ruth TJ; Stoessl AJ
Synapse; 2009 Aug; 63(8):713-6. PubMed ID: 19391152
[TBL] [Abstract][Full Text] [Related]
11. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
[TBL] [Abstract][Full Text] [Related]
12. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
Rodriguez M; Lera G; Vaamonde J; Luquin MR; Obeso JA
J Neurol Neurosurg Psychiatry; 1994 May; 57(5):562-6. PubMed ID: 8201324
[TBL] [Abstract][Full Text] [Related]
13. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
Troiano AR; de la Fuente-Fernandez R; Sossi V; Schulzer M; Mak E; Ruth TJ; Stoessl AJ
Neurology; 2009 Apr; 72(14):1211-6. PubMed ID: 19020294
[TBL] [Abstract][Full Text] [Related]
14. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
15. The pattern of striatal dopaminergic denervation explains sensorimotor synchronization accuracy in Parkinson's disease.
Miller NS; Kwak Y; Bohnen NI; Müller ML; Dayalu P; Seidler RD
Behav Brain Res; 2013 Nov; 257():100-10. PubMed ID: 24076152
[TBL] [Abstract][Full Text] [Related]
16. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
17. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
Harder S; Baas H; Rietbrock S
Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
[TBL] [Abstract][Full Text] [Related]
18. Striatal denervation pattern predicts levodopa effects on sequence learning in Parkinson's disease.
Kwak Y; Bohnen NI; Müller ML; Dayalu P; Seidler RD
J Mot Behav; 2013; 45(5):423-9. PubMed ID: 23971968
[TBL] [Abstract][Full Text] [Related]
19. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover.
de la Fuente-Fernández R; Lu JQ; Sossi V; Jivan S; Schulzer M; Holden JE; Lee CS; Ruth TJ; Calne DB; Stoessl AJ
Ann Neurol; 2001 Mar; 49(3):298-303. PubMed ID: 11261503
[TBL] [Abstract][Full Text] [Related]
20. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
